eligibility_summary
Eligibility: Adults ≥18 with recurrent/progressive IDH‑mutant, 1p/19q‑codeleted oligodendroglioma (WHO 2–3) >12 wks post‑RT, KPS ≥60, surgical/biopsy candidate, adequate labs, WOCBP neg test + contraception. Exclusions: prior progression on anti‑IDH, invasive cancer <3 yrs, leptomeningeal, infratentorial/extracranial, or multifocal disease, dex ≥4 mg/day, HIV/HBV/HCV, active infection or autoimmune on immunosuppression, pregnancy/lactation, recent investigational therapy, major cardiac/pulmonary/hepatic/psychiatric illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Phase 1 single-arm study combining multi-antigen autologous dendritic-cell vaccination and adoptive T-cell therapy with IDH inhibition in recurrent IDH-mutant oligodendroglioma. Interventions: TTRNA-DC vaccines with GM-CSF (biologic, autologous DCs pulsed with total tumor RNA to present broad tumor antigens and prime T cells), TTRNA-xALT (cell therapy, single IV infusion of ex vivo expanded autologous tumor-reactive T cells), non-myeloablative cyclophosphamide/fludarabine (lymphodepletion), autologous CD34+ HSC rescue, tetanus-diphtheria vaccine (protein vaccine adjuvant/recall to enhance DC activation/trafficking), concomitant IDH1/2 inhibitors (small-molecule enzyme inhibitors lowering 2-HG). Targets: DCs and T-cell activation/expansion (CD4+/CD8+), myeloid recruitment via GM-CSF, mutant IDH1/2 metabolic pathway, and hematopoietic reconstitution to support T-cell engraftment.